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Smry A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special
reference to their diagnostic usefulness in pancreatic cancer. CA242 showed senstivity similar to that of
CA19-9 for overall ca and early cases (stage I tumour) of pancreatic cancr. For other mali the
positive rates of CA242 were lower than those of CAI9-9 cxcept for cok_ Ia cancer. An important
characteristic of CA242 was that it was only slightly and infrequently elevated in the sera of patients with
benign dsea such as chronic pancreatitis, chronic hepatitis and liver cirrhosis. This characteristic was more
apparent in the patients with benign obstructive jaundice, indicating that the srum kvel of this marker was
scarcely affected by choletasis. Using cut-off levels corresponding to a 90% specificity, the clnical results
obtained with CA242 in the diags ofpancreatic caner were simila to those obtained with CA19-9, except
that CA19-9 was falsely negtive in some patients with early-stage pancreatic cancer. These finding sugge
the usefulness of this marker for screeni panrneatic cancer patients on their first hospital vit. However,
CA242 was found to be inen by the Lewis blood group sysem This unfavourable reu is attributed to
the C241 catcher antibody of this assay system, which has alnost the same epitope specitity as the C50 and
the NS19-9 monoclonal antibodies. In conusio, CA242 is superior to CA19-9 in diagning pancreatic
cancer by virtue of its higher specificity.
The therapeutic results and prognosis of adenocarcinoma of
the exocrine pancreas are poor, because almost all patients
are already in an advanced stage at diagnosis. Methods for
early detection are urgently needed to improve this situation.
For this purpose, mass screening studies on asympomatic
individuals or outpatients on their first visit have been carried
out using the serum assay of CAl9-9, which has been widely
used as a tumour marker for the diagnosis of pancreatic
cancer (Koprowski et al., 1979; Frebourg et al., 1988;
Homma & Tsuchiya, 1991). Although the efficiencies of these
studies were controversial, outpatient screening was revealed
to be useful in detecting some curable cases of pancreatic
cancer (Homma & Tsuchiya, 1991). However, false-positive
elevation of serum CAl9-9 has been noted, especlly in
benign hepatobiiary disases and chronic pancreatitis, which
are so tmes difficult to differentiate from pancreatic cancer
at the time of admission (Frebourg et al., 1988). The false
positivity leads to further examinations, such as computerised
tomography (CT) or endoscopec retrograde cholangiopan-
creatography (ERCP), which are wasteful of these facilities.
To improve the effectiveness of the screening tests for pan-
creatic cancer, it is necessary to use more cancer-specific
tumour markers without reducing the sensitivity attained by
CAl9-9.
CA242 is a cancer-associated glycoconjugate expressed in
mucin and found predominantly in the sera of pancreatic
cancer patients (Lindholm et al., 1985). The struture of
CA242 has not been fullly elucidated, but it is different from
other established cancer-associated glycoconjugates, such as
sialosyl-fucosyl-lactotetraose or sialosyl lactotetraose
(Johanson et al., 1991a; Kuusela et al., 1991). A sensitive
serum assay system using ime-resolved fluoroimmunoassay
(TRFIA) was developed, and favourable clinical results were
reported for the diagosis of pancreatic cancer, colorectal
cancer and other digestve tract malignancies (Kuusela et al.,
1991; Nilsson et al., 1992; Pasanen et al., 1992). With respect
to the diagnosis of pancreatic cancer, CA242 has been dem-
onstrated to have sensitivity close to or slightly lower than
that of CAl9-9 but it is more specific (Nilsson et al., 1992;
Pasanen et al., 1992; Banfi et al., 1993; Rothlin et al., 1993).
In benign pancreatic and hepatobiliary diseases, the CA242
Correspondence: S. Kawa.
Received 2 August 1993; accepted in revised form 25 January
1994.
level is less frequently elevated. In addition, like CA19-9, it is
elevated in the sera of half of the patients with resectable
pancreatic cancer (Kuusela et al., 1991). However, these
studies have not provided conclusive results of the CA242
assay in benign dias, especialy chronic pancreatitis,
chronic bepatitis and liver cirrhosis, because of the small
number of test samples. In the present study, we compared
CA242 and CA19-9 assays using over a hundred srum
samples each from patients with pancreatic cancer, chronic
pancreatitis, chronic hepatitis and liver cirrhosis. In addition,
we tried to clarify whether or not CA242 can compensate for
some of the drawbacks of CAl9-9, such as the influence of
the Lewis blood group system.
Materials adi
Patients
Serum CA242 levels were measured in 65 normal subjects
and 947 patients with benign and malignant dis listed in
Table I, using retrospectively collected samples. The diag-
nosis of malignant disase was based on clinical examination
and histologial confirmation for operative cases. Among 151
patients with pancreatic cancer, staging was done for the 89
patients whose detailed hospital records were available using
Tab I Number of patients with beign and malignant diseases
studied
Dinosis n
Malgnant disea
Pareatic cancer 151
Gastric cancer 107
Colorectal cancer 39
Biiary tract cancer 31
Oesophageal canr 14
Lung cancer 32
Hepatoma 122
Benign disea
Chronic pancreatitis 105
Chronic hepatitis 180
Liver cirhosis 162
Obstuctive jaundice 14
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the TMN staging system for cancer of the exocrine pancreas
advocated by UICC. The diagnois of chronic pancreatitis
was confirmed by fint of at kast one of the folowing
criteria proposed by the Japanese Society of Gastro-
enterology: (a) the significnt change in the pancreatogram as
shown by ERCP, (b) califiction of the pancreas, (c)
snificant impairment of exocrine function as shown by
pancreozym in-secretn test or secreti test, and (d) his-
tological confirmation at laparotomy. Serum samples were
obtained at a time when patients were free from acute
disease. The diagnosis of chronic hepatitis and liver cirrhosis
was based on histological findings. To confirm the effect of
cholestasis on the serum elevation of the two markers, the
sera ofpatients with benign obsuctivejaundice, for example
due to a common bile duct stone or retroperitoneal fibrosis,
were assayed. In normal subjects, Lewis blood group
phenotypes were confirmed by agglutinaton testing.
The serum samples were obtained by venipuncture and
stored at -20 C before analysis.
Assays
Serum CA242 levels were measured by a dissociation-
enhanced lanthanide fluoroimmunoaay (DELFIA) (Wallac
Oy, Turku, Finland), in which C241 and C242 monoclonal
antibodies were used as catcher and tracer antibodies respec-
tively, according to the manufacturer's instructions. In this
study, the cut-off level of CA242 was established from the
results of normal subjects and by the receiver operating
characteristic (ROC) curve from the results of the patients
with pancreatic cancer and benign dieases including chronic
pancreatitis, chronic hepatitis and liver cirrhosis. Serum
CA19-9 levels were measured by a radioinmunoassay kit
(Centcor, PA, USA), applying the recommended cut-off level
of 37 Uml-1, which was established from results in normal
subjects (Del Villano et at., 1983) and is widely used in
Japan. Clinical results of both markers were also compared
at 90% specificity for the differentiation between pancreatic
cancer and benign diseases.
Statistical analysis
The differences among each Lewis phenotype group in nor-
mal subjects were evaluated by analysis of variance
(ANOVA). A value of P<0.05 was regarded as statistically
significant.
Reslts
ROC analysis
Tlhe ROC analysis showed that the CA242 test was more
sensitive than the CAl9-9 test at specificity levels of 75-95%
(Figure 1).
Sensitivities in various diseases
In this study, the cut-off level of CA242 was defined as
30 Uml-', calculated from the mean + 3 s.d. of serum kvels
in the normal subjects. As shown by the ROC curve (Figure
1), this vahle gives the best discrimination betwen pancreatic
cancer and benign diseases. In addition, cut-off klevls corre-
sponding to a 90% specificity were also caklulated from the
ROC curves as 26 and 47Uml-' for CA242 and CAI9-9
respectively.
Figure 2a summarises the sensitivities in various conditions
at the cut-off levels obtained from normal subjects (CA242,
30 Uml-'; CA19-9, 37 Uml-'). The sensitivity of CA242 in
151 pancreatic cancer patients was high (79%) and similar to
that of CA19-9 (82%). In other malignant diseases, the sen-
sitivity of CAl9-9 was higher than that of CA242 except for
colorectal cancer. In addition, a significant difference in sen-
sitivity between the two markers was observed in patients
with hepatoma, the positive rate for CA242 being 7% and
that for CAl9-9 35%. In benign diseases, serum CA242
levels were less frequently elevated than those of CA19-9.
There were marked differences in the positive rates and
actual values of the two markers in patients with benign
obstructivejaundice (Figure 3), indicating that CA242 is only
slightly affected by cholstasis. This weak effect ofcholstasis
on the sern elevation may account for the lower positive
rates of this marker in benign hepatic diseases and hepatoma
compared with CA19-9.
The sensitivities of the two markers were also compared
using cut-off levels corresponding to a 90% specificity
(Figure 2b). The sensitivity of CA242 in pancreatic cancer
(81%) was again similar to that of CAl9-9 (79%). The
sensitivity ofCA242 in colorectal cancer was twice as high as
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that of CA19-9. In benign obstructive jaundice, the sensitivity
of CA242 was significantly lower than that of CAl9-9.
Comparison ofCA242 and CA19-9 in benign pancreatic and
liver diseases
The actual values of the two markers were compared in
patients with chronic pancreatitis and benign liver dises, in
whom the level of the two markers exceeded the cut-off levels
obtained from normal subjects (Figure 4). In such benign
conditions, the positivity ofCA242 was not as high as that of
CAl9-9, and the level scarcely exceeded 100 U ml,
although the cut-off levels were similar.
Correlation between positive ratio and TMN staging ofthe
pancreatic cancer
To confirm the diagnostic efficiency of the two markers for
early-stage pancreatic cancer, the results obtained by TMN
staging (UICC) were compared using various cut-off levels
(Table II). For stage I tumours, including almost all patients
undergoing curative operation, the positivity of CA242
(41%) was similar to that of CAl9-9 (47%) using the cut-off
levels obtained from normal subjects. However, CAl9-9 was
falsely negative in some patients with stage I tumours using
cut-off levels corresponding to 90% specificity against various
benign conditions. These results indicated that for CA19-9 it
was preferable to use the cut-off level obtained from normal
300
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.
subjects for the detection of early-stage pancreatic cancer,
and the comparison of diagnostic utility should be done at
this cut-off level.
Comparison ofsensitivity andspecificity in diagnosing
pancreatic cancer
The sensitivity and speificity of the two markers in the
diagnosis of pancreatic cancer were compared using cut-off
levels obtained from normal subjects (Table III). Although
the sensitivities of the two markers were imilar, the
specificity of CA242 was higher than that of CAI9-9 cal-
culated from the results of chronic pancreatitis, benign liver
diseases and both conditions combined.
Correlation between serun levels ofthe two markers
As shown in Figure 5, there was no correlation between the
serum levels of the two markers in pancreatic cancer or
benign diseases.
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Fge 3 Scattergram of serum klvels of the two markers in
benign obstructive jaundice. Bars indicate cut-off level (CA242,
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patients with chronic pancreatitis (0), chronic hepatitis (0) and
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Table m Compaison of sensitivity and specificity m
pancreatic cancer
CA242(%) CAJ9-9(%)
Sensitivity 79 82
Specificity
vs CP, I LC 93 85
VsCP 86 76
vs CK LC 95 88
CP, chronic pancreatitis; CH, chronic hepatitis; LC, hvercirrhosis.
Cut-offkvels: CA242, 30 Umrl'; CA19-9, 37 Uml-'.
Tablk n Positive ratio for CA242 and CAI9-9 in panceatic cancer by TMN staging (UICC)
Cut-off Stage I Stage nI Stage IH sage IV
(Ulml-') (n= 17) (%) (n=9) (%) (n=20) (%) (n=43) (%)
Cut-offleelfrorn normal subjects
CA242 30 41 89 85 93
CA19-9 37 47 78 85 91
Cut-offlevel at 90% specificityfor CP, CH, LC
CA242 26 41 89 90 93
CA19-9 47 35 78 85 91
Cut-offlvel at 90% specificityfor CP
CA242 35 41 89 80 88
CA19-9 80 29 78 70 88
Cad-offlevel at 90%/. specficityfor CH, LC
CA242 23 47 89 90 93
CA19-9 42 35 78 85 91
CP, chronic pancreatitis; CH, chronic hepatitis, LC, hver cirrhosis.
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Figwe 6 Influence of Lewis blood group system on serum
CA242 and CA19-9 levels in 65 normal subjects. Determination
of Lewis blood group was performed by haemagglutination test.
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Figre 5 Correlations between serum levels of the two markers
in pancreatic cancer (a) and benign diseases (b).
Influence ofLewis blood group system on sernm levels in
normal subjects
As shown in Figure 6, the serum CA242 levels in normal
subjects were influenced by the Lewis blood group system, as
was the serum CA19-9 level. Among the three phenotypes, a
significantly lower level was found in Le(a-b-) and
Le(a-b+) groups than in the Le(a+b-) group.
Mcsson
In this study, we confirmed that CA242 is a more useful
marker than CA19-9 for detecting curable cases of pancreatic
cancer among outpatients on their first visit, because of the
similar sensitivities for overall cases and cases of early-stage
(stage I) pancreatic cancer, and the higher specificity resulting
from the less frequent and lower elevation in benign diseases.
These results were similar to previous reports (Kuusela et al.,
1991; Nilsson et al., 1992; Pasanen et al., 1992) and superior
to other studies (Banfi et al., 1993; Rothlin et al., 1993).
Although CA19-9 has been widely used as a tumour marker
for the diagnosis of pancreatic cancer, some clinical draw-
backs have been raised concerning false-negative results in
many patients with localised pancreatic cancer (Steinberg et
al., 1986; Malesci et al., 1987; Frebourg et al., 1988; Kawa et
al., 1990), false-positive results in patients with benign
diseases, especially chronic pancreatitis (Schmigel et al., 1985;
Tatsuta et al., 1985; Malesci et al., 1987; Kawa et al., 1990)
and liver diseases (Jalanko et al., 1984; Steinberg et al., 1986;
Kawa et al., 1990; Kobayashi et al., 1991) and false-negative
results in cancer patients with Lewis-negative phenotype
(Hirano et al.. 1987; Margaret et al., 1987; Kawa et al.,
1991).
The clinical usefulness of CAI9-9 in this study was similar
to that reported previously, supporting the validity of the
present study. The sensitivity of CA242 for pancreatic cancer
was similar to that of CAI9-9, and CA242 has been reported
to be expressed on pancreatic cancer tissues to a similar
extent as CA19-9 (Haglund et al., 1989). However, no rela-
tionship was observed between the serum levels of the two
markers in this study. As suggested previously (Johanson et
al., 1991a-, Kuusela et al., 1991), the two structures may be
different. The overall sensitivity of CA242 in other malignant
diseases is lower than that of CA19-9. However, for other
malignancies, more useful diagnostic tools than tumour
markers can be used. Therefore, these disadvantages are
negligible in the clinical use of this marker. On the other
hand, CA242 gave better results in colorectal cancer than
CA19-9, which is in agreement with previous findings
(Kuusela et al., 1991; Nilsson et al., 1992). Its usefulness was
more apparent at cut-off levels corresponding to 90% speci-
ficity. Moreover, CA242 has been reported to be useful in the
diagnosis of early-stage colorectal cancer (Dukes' A and B)
and a valuable complement to CEA (Kuusela et al., 1991;
Nilsson et al., 1992). In hepatoma, a significant difference in
the positive rate was noted between the two markers. CA19-9
is expressed not on hepatoma cells but on bile duct cells. The
mechanism of serum elevation of CA19-9 is considered to be
cholestasis or damage to the bile duct cells (Kobayashi et al.,
1991). Although the exact mechanism of this elevation has
not been elucidated, CA242 may be only slightly affected by
these abnormal conditions, which was further demonstrated
by the results obtained in the patients with benign obstruc-
tive jaundice.
We have confirmed that CA242 is as useful as CA19-9 in
the diagnosis of stage I pancreatic cancer, including curative
resectable disease, using the cut-off level obtained from nor-
mal subjects. By using cut-off levels corresponding to 90%
specificity for various benign conditions, CA19-9 was falsely
negative in some patients with stage I tumour, although the
sensitivities of the two markers overall were similar. Resec-
tability is considered to be an important predictor of the
prognosis (Saito, 1990), and CA19-9 has been reported to be
useful in the diagnosis of 50-79% of patients with resectable
pancreatic cancer (Sakahara et al., 1986, Kawa et al., 1990;
Kobayashi et al., 1991). As with CA19-9, CA242 has also
been reported to be positive in half of patients with resec-
.
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table disease (Kuusela et al., 1991). However, it may be
clinically impractical to search for early pancreatic cancer
such as stage I tumours more extensively using a tumour
marker alone, and it is necessary to develop a screening
system combined with other methods, such as ultrasonog-
raphy, to improve the usefulness of the early diagnosis.
The major advantage of CA242 over CAl9-9 is its higher
specificity resulting from the less frequent and only slight
elevation in the serum level in patients with chronic pan-
creatitis, benign liver diseases and benign obstructive jaun-
dice, which was confirmed by the present study and previous
reports (Johansson et al., 1991b; Kuusela et al., 1991; Nilsson
et al., 1992; Pasanen et al., 1992). The differential diagnosis
of pancreatic cancer from chronic pancreatitis is sometimes
difficult. In patients with liver diseases, false-positive eleva-
tion of CA19-9 is frequently on the first visit to the clinic
(Frebourg et al., 1988). Accordingly, the good discrimination
provided by CA242 will avoid unnecessary further examina-
tion of the patient. CAI9-9 has been demonstrated to be
expressed on the duct cells of the pancreas and bile duct cells
of the liver (Arends et al., 1983; Kobayashi et al., 1991) and
secreted in the pancreatic juice and bile in both healthy
subjects and patients with pathological conditions (Schmiegel
et al., 1985). In benign diseases, the antigen is considered to
be released into the circulation by stagnation of pancreatic
juice, cholestasis or damage to the pancreatic and bile duct.
However, tissue expression of CA242 in the normal pancreas
and in chronic pancreatitis is reported to be similar to that of
CA19-9 (Haglund et al., 1989). Therefore, it is uncertain why
CA242 is less influenced by these conditions. A notable
characteristic of CA242 is that its serum level is scarcely
affected by cholestasis, which was demonstrated by less fre-
quent and slight elevation in sera of patients with benign
obstructive jaundice. The clinical results obtained in benign
liver diseases may also be associated with this characteristic.
Further studies, including immunohistochemistry, are neces-
sary to clarify the exact mechanism.
In this study, the CA242 assay system was shown to be
influenced by the Lewis blood group system, as in the CA19-
9 assay. This drawback is considered to be attributable to the
C241 catcher antibody of the assay system, because the C241
monoclonal antibody has almost the same epitope specificity
as the NSl9-9 monoclonal antibodies used in the CA50 and
CA19-9 assay systems, whereas the C50 antibody also recog-
nises sialylated lact-N-tetraose to a small degree (Nilsson et
al., 1985; Johansson et al., 1991a). In a previous study, we
confirmed that the plasma expression of CA50 is similar to
that of CAl9-9 with respect to Lewis blood cell status (Kawa
et al., 1991). We also found that Lewis-negative patients
constituted one-third of the CA19-9-negative patients, and
the Dupan-2 assay provides a complementary method for
these patients (Kawa et al., 1991). Accordingly, for CA242-
negative patients who are suspected to have pancreatic
cancer, an additional Dupan-2 assay is recommended.
In conclusion, CA242 is superior to CA19-9 in the diag-
nosis of pancreatic cancer because of its higher specificity,
and it may be useful in the screening of localised or resec-
table tumours.
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